D-Glucose transport and D-glucose inhibitable [3H]cytochalasin B binding to jejunal basolateral membrane vesicles were measured to investigate the possible association between changes in transport activity seen in hyperglycemia and density of transporter sites. Comparison was made between hyperglycemic animals, noninfused rats, and a group infused with sorbitol. Vascular infusion of D-glucose produced a rapid increase in D-glucose transport followed by a delayed and smaller increase in [3H]cytochalasin B binding. The Vmax for glucose uptake was increased after only 30 min of glucose infusion and continued to rise up to 6 h. Comparison with noninfused and sorbitol-infused controls showed that 2 h of glucose infusion produced a 3.5-fold increase in the Vmax for D-glucose uptake while D-glucose-inhibitable binding of [3H]cytochalasin B was unaffected. Six hours of hyperglycemia resulted in the further stimulation of glucose transport (4.1-fold) and a significant 1.8-fold increase in cytochalasin B binding over that for noninfused animals. Vesicles prepared from animals 4 h after an in vivo injection of cycloheximide showed an 80% reduction in glucose transport with no significant change in the cytochalasin B binding density. These results suggest that D-glucose transport in the basolateral membrane is regulated by a combination of a modulation of carriers already in the membrane and subsequent changes in carrier site density.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1152/ajpgi.1989.256.5.G878 | DOI Listing |
Ann Pharmacother
January 2025
Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further.
Data Source: A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms.
Nat Rev Nephrol
January 2025
New York University Grossman School of Medicine, New York, NY, USA.
The timely and rational institution of therapy is a key step towards reducing the global burden of chronic kidney disease (CKD). CKD is a heterogeneous entity with varied aetiologies and diverse trajectories, which include risk of kidney failure but also cardiovascular events and death. Developments in the past decade include substantial progress in CKD risk prediction, driven in part by the accumulation of electronic health records data.
View Article and Find Full Text PDFNat Rev Dis Primers
January 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians University, Munich, Germany.
Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death.
View Article and Find Full Text PDFFood Chem
January 2025
Xiamen Medical College, Xiamen, Fujian 361023, China. Electronic address:
This study analyzed dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides from Tartary buckwheat (Fagopyrum tataricum) protein hydrolysates, known for managing chronic diseases. Simulated gastrointestinal digestion enhanced the inhibitory activity of DPP-IV. Using anion-exchange resin DEAE-52, reverse high-performance liquid chromatography, and LC-MS/MS, eight novel peptides were identified.
View Article and Find Full Text PDFDiabetes Ther
January 2025
The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.
Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!